Eli Lilly (LLY)

Hims & Hers Health inked a deal with Eli Lilly on Friday to sell the company's obesity drugs.

They have both outperformed the broader equity market over the long run.

Investors should look to defensive stocks in the healthcare sector during a major market correction.

Sale of BioReference brings $722 million in cash as the company narrows its focus to biotech.

Six tech stocks make up nearly a third of the S&P 500. Here's how AI spending is shaping each one's results.

Animal health company Elanco (NYSE:ELAN) will be reporting results this Friday before market hours. Here’s what to expect. Elanco beat analysts’ revenue expe...

Many megacap growth stocks are underperforming the major indexes this year.

Some individual stocks keep falling. The broader U.S. stock market has always bounced back.

Viking aims to enter the weight loss drug market.

Specialty pharmaceutical company ANI Pharmaceuticals (NASDAQ:ANIP) will be reporting earnings this Thursday before market open. Here’s what investors should ...

Animal health company Zoetis (NYSE:ZTS) will be reporting earnings this Thursday before market hours. Here’s what to look for. Zoetis missed analysts’ revenu...

Medication company Viatris (NASDAQ:VTRS) will be announcing earnings results this Thursday before market hours. Here’s what investors should know. Viatris be...

Pharmaceutical company Amphastar Pharmaceuticals (NASDAQAMPH) will be reporting results this Thursday after market close. Here’s what to look for. Amphastar ...

Pharmaceutical company Collegium Pharmaceutical (NASDAQ:COLL) will be announcing earnings results this Thursday before the bell. Here’s what investors should...

These high-yielding stocks pay up to 7.4% in dividends.

Animal health products manufacturer Phibro Animal Health (NASDAQ:PAHC) will be announcing earnings results this Wednesday after market hours. Here’s what inv...

The company just released some incredible quarterly results, but its valuation is also fairly high.

The drugmaker continues its impressive run.

Compares the Roundhill GLP-1 & Weight Loss ETF (OZEM) and the newer REX Peptide ETF (PEPT), examining holdings, fees, and overlap as GLP-1 drug demand from Eli Lilly and Novo Nordisk continues to grow.

The market for GLP-1 drugs is forecast to explode. It may be understated still.

Trial results for its weight loss drugs could justify a higher valuation for the clinical-stage biotech.

Pharmaceutical company Amneal Pharmaceuticals (NASDAQ:AMRX) will be reporting results tomorrow before market hours. Here’s what to expect. Amneal beat analys...

Global pharmaceutical company Pfizer (NYSE:PFE) will be reporting results this Tuesday before market open. Here’s what to expect. Pfizer beat analysts’ reven...

Biopharma company Corcept Therapeutics (NASDAQ:CORT) will be announcing earnings results this Tuesday after market hours. Here’s what to look for. Corcept be...

Eli Lilly posted 39% YOY revenue growth in Q3 2026 on strong Mounjaro and Zepbound sales, raising full-year guidance even as Medicare's GLP-1 Bridge program pressures drug pricing.